Nationwide Fund Advisors held its position in Albany Molecular Research, Inc. (NASDAQ:AMRI) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,213 shares of the biotechnology company’s stock at the close of the 2nd quarter. Nationwide Fund Advisors’ holdings in Albany Molecular Research were worth $330,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Ameriprise Financial Inc. increased its holdings in shares of Albany Molecular Research by 1.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 119,580 shares of the biotechnology company’s stock worth $2,595,000 after purchasing an additional 1,795 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Albany Molecular Research by 6.1% in the 2nd quarter. Teachers Advisors LLC now owns 46,562 shares of the biotechnology company’s stock worth $1,010,000 after purchasing an additional 2,671 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Albany Molecular Research by 1,274.7% in the 2nd quarter. Alliancebernstein L.P. now owns 331,999 shares of the biotechnology company’s stock worth $7,204,000 after purchasing an additional 307,849 shares in the last quarter. Kennedy Capital Management Inc. bought a new stake in shares of Albany Molecular Research in the 2nd quarter worth $4,423,000. Finally, Keybank National Association OH increased its holdings in shares of Albany Molecular Research by 10.7% in the 2nd quarter. Keybank National Association OH now owns 38,263 shares of the biotechnology company’s stock worth $830,000 after purchasing an additional 3,711 shares in the last quarter. 72.10% of the stock is owned by institutional investors and hedge funds.

WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/10/nationwide-fund-advisors-has-330000-position-in-albany-molecular-research-inc-amri.html.

Albany Molecular Research, Inc. (AMRI) opened at $21.74 on Friday. Albany Molecular Research, Inc. has a 52 week low of $13.01 and a 52 week high of $22.17. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.37 and a current ratio of 0.68.

Separately, BidaskClub downgraded Albany Molecular Research from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Five investment analysts have rated the stock with a hold rating, The company has a consensus rating of “Hold” and a consensus target price of $18.00.

Albany Molecular Research Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Want to see what other hedge funds are holding AMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany Molecular Research, Inc. (NASDAQ:AMRI).

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Stock Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related stocks with our FREE daily email newsletter.